שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

bavarian nordic switzerland ag - virus rabiei inactivatus (stamm: flury lep) - soluzione iniettabile - preparazione cryodesiccata: virus rabiei inactivatus (stamm: flury lep) min. 2.5 u. i., trometamolum, natrii chloridum, dinatrii edetas, kalii hydrogenoglutamas, polygelinum, lo zucchero, il resto: neomycinum nulla, chlortetracyclinum nulla, amphotericinum b nulla, per il vetro. rilascio: acqua iniectabilia q.s. per una soluzione invece di 1 ml. - immunizzazione attiva per la pre - e postexpositionellen tollwutprophylaxe - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - il virus del morbillo casi di vita (stamm: ender s edmonston) virus parotite soggiorno (stamm: jeryl lynn (livello b)), virus della rosolia vivo (stamm: wistar ra 27/3) virus varicellae soggiorno (stamm: oka/merck) - polvere e solvente per sospensione iniettabile - pulver: virus morbilli vivus (stamm: ender's edmonston) min. 3.00 log 10 u., virus parotitis vivus (stamm: jeryl lynn (level b)) min. 4.30 log 10 u., virus rubella vivus (stamm: wistar ra 27/3) min. 3.00 log 10 u., virus varicellae vivus (stamm: oka/merck) min. 3.99 log 10 u., saccharum, gelatina hydrolysata, natrii chloridum, sorbitolum 16 mg, medium 199, natrii hydrogenoglutamas monohydricus, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, natrii hydrogenocarbonas, minimal essential medium (mem), kalii hydrogenophosphas, kalii dihydrogenophosphas, kalii chloridum, neomycinum, phenolsulfonphthaleinum, ureum, acidum hydrochloridum ad ph, natrii hydroxidum ad ph, pro vitro corresp. kalium 0.09 mg, natrium max. 1.75 mg, residui: albuminum humanum. solvens: aqua ad iniectabile. - attiva immunizzazione contro morbillo, parotite, rosolia e varicella, a partire dal 1. fino al 12. compleanno - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - il virus del morbillo casi di vita (stamm edmonston-enders), il virus della parotite soggiorno (stamm jeryl lynn), virus della rosolia vivo (stamm wistar ra 27/3) - polvere e solvente - vaccino attenuatum: il virus del morbillo casi di vita (stamm edmonston-enders) min. 1000 u., virus parotite soggiorno (stamm jeryl lynn) min. 12500 u., virus della rosolia vivo (stamm wistar ra 27/3) min. 1000 u., zucchero, gelatina hydrolysata, sorbitolum, medium199, natrii hydrogenoglutamas monohydricus, minimal essential medium (mem), natrii hydrogenocarbonas, kalii dihydrogenophosphas, dikalii phosphas anhydricus, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, neomycinum, phenolsulfonphthaleinum, albuminum umana, per il vetro. rilascio: acqua iniectabilia 0,5 ml. - attiva immunizzazione contro morbillo, parotite e rosolia, che abbiano compiuto il 12. mese di vita - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

msd merck sharp & dohme ag - virus varicellae vivus - sospensione iniettabile - vaccinum attenuatum: virus varicellae vivus min. 19400 u., saccharum, gelatina hydrolysata, ureum, natrii chloridum, natrii hydrogenoglutamas monohydricus, dinatrii phosphas, kalii dihydrogenophosphas, kalii chloridum, neomycinum, pro vitro. solvens: aqua ad iniectabile. - immunizzazione attiva contro l'herpes zoster e la nevralgia post-erpetica, a partire dai 50. compleanno - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-pdm09: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/cambodia/e0826360/2020 (h3n2)-like: reassortant virus ivr-221 derived from a/cambodia/e0826360/2020) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - toxoidum diphtheriae, toxoidum tetani, toxoidum pertussis, haemagglutininum filamentosum, pertactinum, fimbriae types 2 et 3, virus poliomyelitis typus 1 inactivatus, virus poliomyelitis typus 2 inactivatus, virus poliomyelitis typus 3 inactivatus - suspension injectable en seringue préremplie - toxoidum diphtheriae min. 2 u.i., toxoidum tetani min. 20 u.i., toxoidum pertussis 2.5 µg, haemagglutininum filamentosum 5 µg, pertactinum 3 µg, fimbriae types 2 et 3 5 µg, virus poliomyelitis typus 1 inactivatus 29 u., virus poliomyelitis typus 2 inactivatus 7 u., virus poliomyelitis typus 3 inactivatus 26 u., aluminii phosphas corresp. aluminium 0.33 mg, phenoxyethanolum, ethanolum 1.01 mg, polysorbatum 80, aqua ad iniectabile, ad suspensionem pro 0.5 ml corresp. ethanolum 0.3 % v/v, residui: formaldehydum, glutaralum, streptomycinum, neomycinum, polymyxinum b, albuminum seri bovis. - vaccination de rappel contre la diphtérie, le tétanos, la coqueluche et la poliomyélite chez les personnes à partir du 4ème anniversaire - vaccini

שווייץ - איטלקית - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini